Additional biomarkers whose sensitivity and specificity in diagnosing MDs were confirmed by many studies are fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) [10,11]. This evidence concerns the gene FGF21 and myelodysplastic syndrome.